Two AI diagnostic solutions for breast cancer and colorectal cancer developed by Owkin have been given EU approval.
Cancer patients across the EU can now use two of Owkin’s AI models – one predicting breast cancer relapse after treatment, and another determining whether cases of colorectal cancer are micro-satellite stable or unstable.
By using AI to analyse digital pathology images, they are designed to help clinicians make precision medicine – diagnostic and treatment based on a patient’s individual characteristics – more accessible to more patients at an earlier stage of their disease.
Owkin’s mission is to “join patient care with medical research to discover new mechanisms of diseases and derive better treatments for unmet medical needs.”
AI predicting breast cancer relapse
RlapsRisk BC is the first CE-IVD approved digital pathology-based AI diagnostic that predicts the risk that early breast cancer patients will relapse.
MSIntuit CRC is the first CE-IVD approved AI solution that enables the identification of micro-satellite stable (MSS) patients from routine histology slides, enabling a significant reduction in time and the number of diagnostic tests for detecting MSI in clinical practice.
AI for the “right” cancer treatment
Meriem Sefta, Chief Diagnostics Officer at Owkin, said: “Our mission is to use AI to find the right treatment for every patient.
“Novel drugs allow us to personalize treatments to patients’ individual disease characteristics, promising a new era of precision medicine.
“But one roadblock that doctors face is finding these patients rapidly, accurately and efficiently.
“Our first approved diagnostic solutions could help millions of patients with breast or colorectal cancer to receive the therapies they need sooner.
“This is a crucial moment in Owkin’s mission to use AI to better understand diseases and develop more accurate diagnostics and treatments for patients.”
Don’t miss…
AI catches breast cancer more often than doctors alone
